Harrow Projects Strong 2026 Growth with $350M-$365M Revenue Guidance & New Product Launches
Summary
Harrow, Inc. released a corporate presentation outlining strong 2026 financial guidance with projected revenues of $350M-$365M and Adjusted EBITDA of $80M-$100M, alongside specific timelines for new product launches and operational expansions.
Key Events
-
Issues Strong 2026 Financial Guidance
The company projects full-year 2026 revenues of $350 million to $365 million and Adjusted EBITDA of $80 million to $100 million, indicating significant growth from 2025.
-
Announces Key Product Launch Timelines
New product launches include BYQLOVI in Q2 2026, BYOOVIZ in mid-2026, and OPUVIZ in early 2027, expected to drive future revenue.
-
Details Operational Expansion for VEVYE
Harrow plans to double its VEVYE sales force to 100 representatives by June 2026 and secured preferred status with CVS for the product.
-
Provides IHEEZO Growth Strategy
The company expects improved net pricing for IHEEZO in H2 2026 and anticipates retina-specific clinical data in 2026 to support adoption.
Analysis
This 8-K, furnishing a corporate presentation, provides a highly positive outlook for Harrow, Inc. The company has issued robust full-year 2026 financial guidance, projecting revenues between $350 million and $365 million and Adjusted EBITDA between $80 million and $100 million. This guidance represents substantial growth from 2025 figures and indicates strong confidence in upcoming commercialization efforts. Additionally, the presentation details key product launch timelines for BYQLOVI (Q2 2026), BYOOVIZ (mid-2026), and OPUVIZ (early 2027), alongside significant operational expansions like doubling the VEVYE sales force. These strategic initiatives and financial targets are critical for investors to assess the company's future trajectory and growth potential.
At the time of this filing, HROW was trading at $35.29 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $1.3B. The 52-week trading range was $20.85 to $54.85. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.